Are you Dr. Gheuens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 4 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
330 Brookline Ave
E/Cls-1017
Boston, MA 02215Phone+1 617-735-4468Fax+1 617-735-4527- Is this information wrong?
Summary
- Dr. Sarah Gheuens, MD is a neurologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is an Instructor at Beth Israel Deaconess Medical Center.
Education & Training
- Vrije Universiteit BrusselsClass of 2004
Certifications & Licensure
- MA State Medical License 2011 - 2025
Publications & Presentations
PubMed
- 1 citationsNeuroimaging and pediatric HIV.David Bearden> ;Neurology. Clinical Practice. 2019 Oct 1
- 318 citationsNusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda, Wuh-Liang Hwu, Thomas O. Crawford, Richard S. Finkel, Janbernd Kirschner, Nancy L. Kuntz, Julie A. Parsons, Moni...> ;Neuromuscular Disorders. 2019 Sep 12
- 62 citationsAn Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical TrialsBasil T. Darras, Michelle A. Farrar, Eugenio Mercuri, Richard S. Finkel, Richard Foster, Steven G. Hughes, Ishir Bhan, Wildon Farwell, Sarah Gheuens> ;CNS Drugs. 2019 Sep 1
- Join now to see all
Press Mentions
- Centogene and Agios Expand Rare Blood Disease PartnershipNovember 5th, 2021
- Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin ResponseJune 27th, 2023
- Oral Mitapivat Shows Promise for Non-Transfusion-Dependent Thalassemia in Phase 3 TrialJanuary 11th, 2024
- Join now to see all